A Rapid Urine Test for Early Detection of Kidney Injury

Overview

Journal Kidney Int

Publisher Elsevier

Specialty Nephrology

Date 2009 Apr 24

PMID 19387469

Citations 80

Authors

Vishal S Vaidya

Glen M Ford

Sushrut S Waikar

Yizhuo Wang

Matthew B Clement

Victoria Ramirez

Warren E Glaab

Sean P Troth

Frank D Sistare

Walter C Prozialeck

Joshua R Edwards

Norma A Bobadilla

Stephen C Mefferd

Joseph V Bonventre

Affiliations

Soon will be listed here.

Abstract

Kidney injury molecule-1 (Kim-1) has been qualified by the Food and Drug Administration and European Medicines Agency as a highly sensitive and specific urinary biomarker to monitor drug-induced kidney injury in preclinical studies and on a case-by-case basis in clinical trials. Here we report the development and evaluation of a rapid direct immunochromatographic lateral flow 15-min assay for detection of urinary Kim-1 (rat) or KIM-1 (human). The urinary Kim-1 band intensity using the rat Kim-1 dipstick significantly correlated with levels of Kim-1 as measured by a microbead-based assay, histopathological damage, and immunohistochemical assessment of renal Kim-1 in a dose- and time-dependent manner. Kim-1 was detected following kidney injury induced in rats by cadmium, gentamicin, or bilateral renal ischemia/reperfusion. In humans, the urinary KIM-1 band intensity was significantly greater in urine from patients with acute kidney injury than in urine from healthy volunteers. The KIM-1 dipstick also enabled temporal evaluation of kidney injury and recovery in two patients who developed postoperative acute kidney injury following cytoreductive surgery for malignant mesothelioma with intraoperative local cisplatin administration. We hope that future, more extensive studies will confirm the utility of these results, which show that the Kim-1/KIM-1 dipsticks can provide a sensitive and accurate detection of Kim-1/KIM-1, thereby providing a rapid diagnostic assay for kidney damage and facilitating the rapid and early detection of kidney injury in preclinical and clinical studies.

Citing Articles

Determination of the reference interval for urine kidney injury molecule-1 in 50 healthy cats.

Brown T, Defarges A, Monteith G, Appleby R, Bienzle D J Feline Med Surg. 2024; 26(4):1098612X241238923.

PMID: 38647460 PMC: 11103318. DOI: 10.1177/1098612X241238923.

Development and application of an amplified luminescent proximity homogeneous assay-linked immunosorbent assay for the accurate quantification of kidney injury molecule-1.

Fu Y, Sun D, Qin Y, Zheng T, Zhou Z, Zhou X Front Mol Biosci. 2024; 10:1280681.

PMID: 38304229 PMC: 10832993. DOI: 10.3389/fmolb.2023.1280681.

New perspectives in application of kidney biomarkers in mycotoxin induced nephrotoxicity, with a particular focus on domestic pigs.

Raduly Z, Szabo A, Mezes M, Balatoni I, Price R, Dockrell M Front Microbiol. 2023; 14:1085818.

PMID: 37125184 PMC: 10140568. DOI: 10.3389/fmicb.2023.1085818.

The Potential Protective Effect and Underlying Mechanisms of Physiological Unconjugated Hyperbilirubinemia Mediated by UGT1A1 Antisense Oligonucleotide Therapy in a Mouse Model of Cyclosporine A-Induced Chronic Kidney Disease.

Marghani B, El-Adl M, Ateya A, Othman B, Ghamry H, Shukry M Metabolites. 2022; 12(10).

PMID: 36295901 PMC: 9612357. DOI: 10.3390/metabo12100999.

Glycosylated gold nanoparticles in point of care diagnostics: from aggregation to lateral flow.

Baker A, Hawker-Bond G, Georgiou P, Dedola S, Field R, Gibson M Chem Soc Rev. 2022; 51(16):7238-7259.

PMID: 35894819 PMC: 9377422. DOI: 10.1039/d2cs00267a.

References

Uchino S, Kellum J, Bellomo R, Doig G, Morimatsu H, Morgera S . Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005; 294(7):813-8. DOI: 10.1001/jama.294.7.813. View

Sistare F, DeGeorge J . Preclinical predictors of clinical safety: opportunities for improvement. Clin Pharmacol Ther. 2007; 82(2):210-4. DOI: 10.1038/sj.clpt.6100243. View

Vaidya V, Ozer J, Dieterle F, Collings F, Ramirez V, Troth S . Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010; 28(5):478-85. PMC: 2885849. DOI: 10.1038/nbt.1623. View

Vaidya V, Ramirez V, Ichimura T, Bobadilla N, Bonventre J . Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol. 2005; 290(2):F517-29. DOI: 10.1152/ajprenal.00291.2005. View

Appel G, Neu H . Gentamicin in 1978. Ann Intern Med. 1978; 89(4):528-38. DOI: 10.7326/0003-4819-89-4-528. View

Ichimura T, Hung C, Yang S, Stevens J, Bonventre J . Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol. 2003; 286(3):F552-63. DOI: 10.1152/ajprenal.00285.2002. View

Prozialeck W, Vaidya V, Liu J, Waalkes M, Edwards J, Lamar P . Kidney injury molecule-1 is an early biomarker of cadmium nephrotoxicity. Kidney Int. 2007; 72(8):985-93. PMC: 2747605. DOI: 10.1038/sj.ki.5002467. View

Vaidya V, Ferguson M, Bonventre J . Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol. 2007; 48:463-93. PMC: 2742480. DOI: 10.1146/annurev.pharmtox.48.113006.094615. View

van Timmeren M, Vaidya V, van Ree R, Oterdoom L, de Vries A, Gans R . High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation. 2008; 84(12):1625-30. PMC: 2745062. DOI: 10.1097/01.tp.0000295982.78039.ef. View

10.

Han W, Bailly V, Abichandani R, Thadhani R, Bonventre J . Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002; 62(1):237-44. DOI: 10.1046/j.1523-1755.2002.00433.x. View

11.

van Timmeren M, Bakker S, Vaidya V, Bailly V, Schuurs T, Damman J . Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol. 2006; 291(2):F456-64. DOI: 10.1152/ajprenal.00403.2005. View

12.

Carson R, Vignali D . Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J Immunol Methods. 1999; 227(1-2):41-52. DOI: 10.1016/s0022-1759(99)00069-1. View

13.

Perez-Rojas J, Blanco J, Cruz C, Trujillo J, Vaidya V, Uribe N . Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol. 2006; 292(1):F131-9. DOI: 10.1152/ajprenal.00147.2006. View

14.

Dieterle F, Marrer E, Suzuki E, Grenet O, Cordier A, Vonderscher J . Monitoring kidney safety in drug development: emerging technologies and their implications. Curr Opin Drug Discov Devel. 2008; 11(1):60-71. View

15.

Vaidya V, Waikar S, Ferguson M, Collings F, Sunderland K, Gioules C . Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci. 2009; 1(3):200-8. PMC: 2638059. DOI: 10.1111/j.1752-8062.2008.00053.x. View

16.

Liangos O, Perianayagam M, Vaidya V, Han W, Wald R, Tighiouart H . Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007; 18(3):904-12. DOI: 10.1681/ASN.2006030221. View

17.

Gilbertson D, Liu J, Xue J, Louis T, Solid C, Ebben J . Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol. 2005; 16(12):3736-41. DOI: 10.1681/ASN.2005010112. View

18.

Zhou Y, Vaidya V, Brown R, Zhang J, Rosenzweig B, Thompson K . Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci. 2007; 101(1):159-70. PMC: 2744478. DOI: 10.1093/toxsci/kfm260. View